Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent
In Brief: GAO Says Congress Should Re-Examine Delaney Clause, Consider Making It More Flexible
CALGB Grant OKed, But Group May Lose Support For Its Non-Hematologic Segments
Aging Institute Encourages Cancer Investigators To Include Elderly
BRMP Investigators Find New Lung Tumor Antigen, Seek Developers
Summit Conference Reviews Leads In Leukemia, Lymphoma
Cell Behavior Changes Noted At Baltimore Symposium
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI
